Disc Medicine (NASDAQ:IRON) Insider Sells $511,485.00 in Stock

Disc Medicine, Inc. (NASDAQ:IRON) insider Rahul Khara sold 6,500 shares of the firm’s stock in a transaction that occurred on Friday, January 2nd. The shares were sold at an average price of $78.69, for a total transaction of $511,485.00. Following the completion of the transaction, the insider owned 37,793 shares of the company’s stock, valued at $2,973,931.17. This trade represents a 14.68% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink.

Disc Medicine Price Performance

NASDAQ IRON traded down $0.46 on Monday, hitting $78.63. The stock had a trading volume of 414,028 shares, compared to its average volume of 620,681. The firm has a 50-day moving average of $87.26 and a 200-day moving average of $71.22. The company has a debt-to-equity ratio of 0.05, a quick ratio of 23.45 and a current ratio of 23.45. Disc Medicine, Inc. has a 52-week low of $30.82 and a 52-week high of $99.50. The company has a market capitalization of $2.97 billion, a price-to-earnings ratio of -14.70 and a beta of 0.87.

Disc Medicine (NASDAQ:IRON) last released its quarterly earnings results on Thursday, November 6th. The company reported ($1.77) EPS for the quarter, missing analysts’ consensus estimates of ($1.48) by ($0.29). Equities analysts expect that Disc Medicine, Inc. will post -4.07 EPS for the current year.

Analyst Ratings Changes

A number of analysts have recently issued reports on the company. Morgan Stanley lifted their price target on Disc Medicine from $90.00 to $115.00 and gave the company an “overweight” rating in a research report on Thursday, October 30th. National Bankshares set a $153.00 target price on shares of Disc Medicine in a research note on Friday, October 17th. Cantor Fitzgerald lifted their target price on shares of Disc Medicine from $132.00 to $153.00 and gave the company an “overweight” rating in a research report on Friday, October 17th. Wells Fargo & Company boosted their price target on shares of Disc Medicine from $91.00 to $109.00 and gave the stock an “overweight” rating in a research note on Tuesday, December 16th. Finally, Wedbush raised their price objective on shares of Disc Medicine from $90.00 to $110.00 and gave the company an “outperform” rating in a research report on Friday, October 17th. One investment analyst has rated the stock with a Strong Buy rating, eleven have given a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, Disc Medicine has a consensus rating of “Moderate Buy” and an average target price of $119.00.

Institutional Trading of Disc Medicine

Institutional investors have recently made changes to their positions in the stock. Aster Capital Management DIFC Ltd purchased a new position in shares of Disc Medicine in the third quarter worth $38,000. CWM LLC grew its holdings in Disc Medicine by 213.5% in the 2nd quarter. CWM LLC now owns 1,044 shares of the company’s stock worth $55,000 after acquiring an additional 711 shares during the last quarter. Avanza Fonder AB purchased a new position in shares of Disc Medicine in the second quarter valued at about $57,000. Mirae Asset Global Investments Co. Ltd. raised its stake in shares of Disc Medicine by 15.6% during the second quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,338 shares of the company’s stock valued at $71,000 after acquiring an additional 181 shares during the last quarter. Finally, Ameritas Investment Partners Inc. boosted its holdings in shares of Disc Medicine by 8.9% during the second quarter. Ameritas Investment Partners Inc. now owns 2,515 shares of the company’s stock worth $133,000 after purchasing an additional 206 shares during the period. Hedge funds and other institutional investors own 83.70% of the company’s stock.

Disc Medicine Company Profile

Disc Medicine, Inc (NASDAQ: IRON) is a clinical-stage biotechnology company focused on discovering and developing precision medicines that restore normal cellular function in severe genetic and acquired diseases. The company employs a chemistry-driven approach to identify small molecules that selectively modulate RNA-binding proteins or splicing regulatory pathways. By leveraging proprietary screening and medicinal chemistry platforms, Disc Medicine aims to address diseases with high unmet medical needs and limited treatment options.

The company’s pipeline is anchored by lead programs targeting neuromuscular and hematological disorders.